Myriad Genetics, Inc.(MYGN)

$3.19—

Chart

Myriad Genetics, Inc.(MYGN)

NASDAQ

$3.19—

Chart Studio

MYGN(MYGN)

MYGN

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.16

Nov 2, 2026 · Reports after close

Revenue Estimate

$196M

FY2030E EPS$0.64

Analyst Sentiment

Wall St. Consensus

Hold

33 analysts·High coverage

Score

8 Buy (24%)19 Hold (58%)6 Sell (18%)

Rating Breakdown

Strong Buy

00%

Buy

824%

Hold

1958%

Sell

618%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

-6.0%

Consensus

$3.00

-6.0%

Bull

$6.00

+88.1%

12-Month Target Range33 analysts

$3.00$3.00$6.00

Current $3.19Consensus

Current Price

$3.19

Above Consensus

$0.19

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+5.62%

EPS—

FY2028

Rev+4.79%

EPS—

FY2029

Rev+5.84%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$834M	$881M	$923M	$977M	$1.10B
Low	$799M	$844M	$844M	$935M	$1.05B
High	$850M	$898M	$966M	$996M	$1.12B
EBITDA Avg	$-140M	$-148M	$-155M	$-164M	$-184M
Low	$-143M	$-151M	$-163M	$-168M	$-188M
High	$-134M	$-142M	$-142M	$-157M	$-177M
EBIT Avg	$-205M	$-217M	$-227M	$-241M	$-270M
Low	$-209M	$-221M	$-238M	$-245M	$-275M
High	$-197M	$-208M	$-208M	$-230M	$-258M
Net Income Avg	$3M	$-8M	$-8M	$-7M	$60M
Low	$-164M	$-14M	$-8M	$-7M	$56M
High	$109M	$-2M	$-8M	$-6M	$61M
EPS Avg	$-0.20	$-0.07	$-0.08	$-0.07	$0.64
Low	$-1.76	$-0.15	$-0.09	$-0.07	$0.60
High	$1.17	$-0.02	$-0.08	$-0.07	$0.66
Analysts (Rev / EPS)	6 / 4	6 / 5	6 / 2	4 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$213M	$220M	$210M	$212M	$222M	$226M	$220M	$225M
Low	$212M	$218M	$209M	$210M	$220M	$225M	$218M	$223M
High	$215M	$222M	$212M	$214M	$224M	$229M	$222M	$227M
EBITDA Avg	$-36M	$-37M	$-35M	$-36M	$-37M	$-38M	$-37M	$-38M
Low	$-36M	$-37M	$-36M	$-36M	$-38M	$-38M	$-37M	$-38M
High	$-36M	$-37M	$-35M	$-35M	$-37M	$-38M	$-37M	$-38M
EBIT Avg	$-53M	$-54M	$-52M	$-52M	$-55M	$-56M	$-54M	$-55M
Low	$-53M	$-55M	$-52M	$-53M	$-55M	$-56M	$-55M	$-56M
High	$-52M	$-54M	$-51M	$-52M	$-54M	$-55M	$-54M	$-55M
Net Income Avg	$368,677	$3M	$-6M	$-5M	$-622,930	$606,720	$-948,000	$7M
Low	$322,593	$3M	$-6M	$-5M	$-630,506	$601,042	$-959,527	$7M
High	$373,160	$3M	$-6M	$-5M	$-617,101	$614,098	$-939,128	$7M
EPS Avg	$0.00	$0.04	$-0.06	$-0.05	$-0.01	$0.01	$-0.01	$0.07
Low	$0.00	$0.04	$-0.06	$-0.05	$-0.01	$0.01	$-0.01	$0.07
High	$0.00	$0.04	$-0.06	$-0.05	$-0.01	$0.01	$-0.01	$0.07
Analysts (Rev / EPS)	4 / 5	4 / 4	2 / 1	2 / 1	2 / 1	2 / 1	1 / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

Aug 18, 2026Stephens

Myriad Genetics price target lowered to $3 from $5 at Stephens

Target:$3.00

-1.6%from $3.05

Aug 3, 2026Wells Fargo

Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

Target:$3.00

+4.9%from $2.86

Feb 24, 2026UBS

Myriad Genetics price target lowered to $6 from $8 at UBS

Target:$6.00

+27.5%from $4.71

Nov 4, 2025UBS

Myriad Genetics price target raised to $8 from $6 at UBS

Target:$8.00

-2.2%from $8.18

May 7, 2025Craig-Hallum

Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum

Target:$18.00

+147.6%from $7.27

May 7, 2025UBS

Myriad Genetics price target lowered to $7 from $16 at UBS

Target:$7.00

-3.7%from $7.27

May 7, 2025Wells Fargo

Myriad Genetics downgraded to Equal Weight from Overweight at Wells Fargo

Target:$6.00

-17.5%from $7.27

Mar 12, 2025Piper Sandler

Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler

Target:$12.50

+20.1%from $10.41

Mar 4, 2025Piper Sandler

Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler

Target:$11.50

+10.4%from $10.42

Dec 9, 2024Leerink Partners

Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform

Target:$21.00

+38.6%from $15.15

Oct 14, 2024Scotiabank

Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN)

Target:$34.00

+37.8%from $24.67

Sep 19, 2024Morgan Stanley

Myriad Genetics initiated with an Equal Weight at Morgan Stanley

Target:$32.00

+12.4%from $28.47

Aug 27, 2024Wells Fargo

Myriad Genetics initiated with an Overweight at Wells Fargo

Target:$35.00

+27.3%from $27.50

Aug 7, 2024Guggenheim

Myriad Genetics price target raised to $29 from $25 at Guggenheim

Target:$29.00

+11.7%from $25.96

Jun 26, 2024Scotiabank

Myriad Genetics initiated with an Outperform at Scotiabank

Target:$29.00

+17.8%from $24.62

May 13, 2024Piper Sandler

Myriad Genetics (MYGN) PT Raised to $28 at Piper Sandler

Target:$28.00

+11.7%from $25.07

Dec 21, 2023Piper Sandler

Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation

Target:$23.00

+12.2%from $20.49

Oct 5, 2022Stephens

Stephens starts Myriad Genetics at Equal Weight, sees stock as 'show me story'

Target:$22.00

+5.7%from $20.82

Apr 19, 2022Goldman Sachs

Goldman Sachs Maintains Sell on Myriad Genetics, Lowers Price Target to $23

Target:$23.00

-0.1%from $23.03

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance